Description

Nangibotide TFA is a TREM-1 receptor inhibitor that can modulate innate immune response. Nangibotide TFA can reduce systemic and in situ inflammatory reaction in rodent models of myocardial ischaemia-reperfusion[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C56H83F3N14O24S2—-[1]Cuvier V, et, al. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol. 2018 Oct;84(10):2270-2279.—-1457.46–99.86–CC(O)=O.OC(C=C1)=CC=C1C[C@@H](C(NCC(N[C@@H](CS)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)NC([C@H](CCC(O)=O)NC(CNC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology; Cardiovascular Disease–DMSO : 50 mg/mL (ultrasonic)–Others—-Others–Peptides